Journal
CURRENT TOPICS IN MEDICINAL CHEMISTRY
Volume 14, Issue 16, Pages 1866-1874Publisher
BENTHAM SCIENCE PUBL LTD
DOI: 10.2174/1568026614666140929114822
Keywords
Antituberculosis drug; bedaquiniline; clinical trials; docking; diarylquinolone; Mycobacterium tuberculosis
Categories
Funding
- KU Research Professor Program of Konkuk University, Seoul, South Korea
Ask authors/readers for more resources
Each year, a huge number of new cases accounts of TB with added problems due to multidrug resistant TB varieties. Globally, TB is one of the top causes of loss of life among people living with HIV who are more likely than others to get TB infection. Current TB treatment includes long term administration of cocktail of drugs; hence, the development of an alternative armamentarium against TB is the primary requirement. In fact, new drugs with novel activity against mycobacteria are of significant importance in order to combat existing levels of resistance. The present report covers the discovery of a diarylquinoline TB drug, bedaquiline, its antituberculosis effects and mode of action. Clinical studies conducted on bedaquiline which brought it to the accelerated FDA acceptance have been described. This report is of great attention for therapeutic apothecaries working in TB medication growth in terms of creating further diarylquinoline applicants with a wide variety of antimycobacterial results.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available